Biotech | April 06, 2026
Biocon renames Irish step-down subsidiary as Biocon Biologics Ireland
Move aligns global biologics identity under the Biocon Biologics brand
Move aligns global biologics identity under the Biocon Biologics brand
Wholly owned subsidiary KIMS Swastha signs hospital management and sub-lease deal for 210-bed facility, with option to acquire majority stake later
The deal gives Cupid immediate access to Style Baazar’s fast-growing network of over 260 stores
This marks a meaningful step in the company's continued expansion in the region
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
The showcase, running March 27–31, puts a spotlight on everything from fine lines to daily sun protection
Sugammadex injection is bioequivalent to Merck’s Bridion injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery
Subscribe To Our Newsletter & Stay Updated
